HCA Healthcare, Inc. $HCA Shares Sold by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC cut its holdings in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 6,706 shares of the company’s stock after selling 193 shares during the period. Frank Rimerman Advisors LLC’s holdings in HCA Healthcare were worth $2,569,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Nuveen LLC purchased a new stake in HCA Healthcare during the 1st quarter worth about $569,217,000. Pacer Advisors Inc. increased its stake in shares of HCA Healthcare by 6,237.9% during the first quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock worth $466,815,000 after buying an additional 1,329,618 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in HCA Healthcare by 83.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after acquiring an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of HCA Healthcare by 49.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock valued at $615,583,000 after purchasing an additional 587,036 shares during the last quarter. Finally, Abdiel Capital Advisors LP purchased a new stake in shares of HCA Healthcare during the 1st quarter worth $164,835,000. 62.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HCA has been the subject of a number of recent analyst reports. Wells Fargo & Company lifted their price target on HCA Healthcare from $412.00 to $431.00 and gave the stock an “equal weight” rating in a report on Thursday, November 13th. KeyCorp upped their price target on HCA Healthcare from $465.00 to $475.00 and gave the company an “overweight” rating in a report on Monday, October 27th. Barclays boosted their price objective on shares of HCA Healthcare from $445.00 to $494.00 and gave the stock an “overweight” rating in a research report on Monday, October 27th. The Goldman Sachs Group boosted their price target on shares of HCA Healthcare from $470.00 to $520.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Finally, Bank of America raised their price objective on HCA Healthcare from $430.00 to $470.00 and gave the stock a “neutral” rating in a report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $474.53.

Insider Buying and Selling

In other news, EVP Michael R. Mcalevey sold 3,892 shares of the stock in a transaction that occurred on Wednesday, November 5th. The stock was sold at an average price of $473.79, for a total transaction of $1,843,990.68. Following the completion of the transaction, the executive vice president directly owned 3,487 shares of the company’s stock, valued at approximately $1,652,105.73. This represents a 52.74% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 3,836 shares of the company’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the transaction, the executive vice president directly owned 31,503 shares in the company, valued at $13,194,716.52. This represents a 10.85% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.30% of the stock is currently owned by insiders.

HCA Healthcare Stock Up 0.9%

NYSE HCA opened at $477.07 on Tuesday. HCA Healthcare, Inc. has a 52-week low of $289.98 and a 52-week high of $480.00. The business’s 50-day moving average price is $434.74 and its 200 day moving average price is $397.75. The firm has a market cap of $108.86 billion, a P/E ratio of 18.44, a P/E/G ratio of 1.38 and a beta of 1.41.

HCA Healthcare (NYSE:HCA) last released its earnings results on Friday, October 24th. The company reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.64 by $1.32. HCA Healthcare had a negative return on equity of 792.25% and a net margin of 8.53%.The business had revenue of $19.16 billion for the quarter, compared to analyst estimates of $18.55 billion. During the same quarter in the previous year, the company posted $4.90 earnings per share. The company’s revenue for the quarter was up 9.6% compared to the same quarter last year. HCA Healthcare has set its FY 2025 guidance at 27.000-28.000 EPS. As a group, analysts anticipate that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 29th. Investors of record on Monday, December 15th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, December 15th. HCA Healthcare’s dividend payout ratio is currently 11.13%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.